Stopping Cancer in its Tracks: Using Small Molecular Inhibitors to Target Glioblastoma Migrating Cells

Author(s): Austin K. Mattox, Jing Li, David C. Adamson

Journal Name: Current Drug Discovery Technologies

Volume 9 , Issue 4 , 2012

Become EABM
Become Reviewer


Glioblastoma multiforme (GBM) represents one of the most common aggressive types of primary brain tumors. Despite advances in surgical resection, novel neuroimaging procedures, and the most recent adjuvant radiotherapy and chemotherapy, the median survival after diagnosis is about 12-14 months. Targeting migrating GBM cells is a key research strategy in the fight against this devastating cancer. Though the vast majority of the primary tumor focus can be surgically resected, these migrating cells are responsible for its universal recurrence. Numerous strategies and technologies are being explored to target migrating glioma cells, with small molecular inhibitors as one of the most commonly studied. Small molecule inhibitors, such as protein kinase inhibitors, phosphorylation site inhibitors, protease inhibitors, and antisense oligonucleotides show promise in slowing the progression of this disease. A better understanding of these small molecule inhibitors and how they target various extra- and intracellular signaling pathways may eventually lead to a cure for GBM.

Keywords: Glioblastoma, glioma cell, migration, small molecular inhibitor, brain tumors, protein kinase inhibitors, phosphorylation site inhibitors, protease inhibitors, antisense oligonucleotides, intracellular signaling pathways

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [294 - 304]
Pages: 11
DOI: 10.2174/157016312803305924
Price: $65

Article Metrics

PDF: 30